Cargando…
Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease
BACKGROUND: Alzheimer’s disease (AD) is associated with progressive impairments in brain responsiveness to insulin and insulin-like growth factor (IGF). Although deficiencies in brain insulin and IGF could be ameliorated with trophic factors such as insulin, impairments in receptor expression, bindi...
Autores principales: | Reich, D, Gallucci, G, Tong, M, de la Monte, SM |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350901/ https://www.ncbi.nlm.nih.gov/pubmed/30705969 http://dx.doi.org/10.13188/2376-922X.1000025 |
Ejemplares similares
-
Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015) -
PPARγ and PPARδ as Modulators of Neoplasia and Cell Fate
por: Glazer, Robert I., et al.
Publicado: (2008) -
Ligand Modulated Antagonism of PPARγ by Genomic and Non-Genomic Actions of PPARδ
por: Gustafsson, Mattias C. U., et al.
Publicado: (2009) -
NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis?
por: Mackenzie, Gerardo G., et al.
Publicado: (2008) -
PPARδ, a Potential Therapeutic Target for Heart Disease
por: Yang, Qinglin, et al.
Publicado: (2018)